September 22, 2020

To,
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To,
The Manager
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol - Biocon

Subject: Change in Key Managerial Personnel of the Company.

Dear Sir/Madam,

With reference to the captioned subject, pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform you that the Board of Directors at its meeting held today, has approved the following changes in Key Managerial Personnel of the Company:

- Appointment of Mr. Anupam Jindal as Chief Financial Officer of the Company effective from conclusion of this Board Meeting;
- Step down of Mr. Indranil Sen from the position of Interim Chief Financial Officer effective from conclusion of this Board Meeting and he will continue as Vice-President, Finance.

In compliance with Regulation 30 of SEBI Listing Regulations, please find enclosed herewith the required disclosures as Annexure A and a press release titled “Biocon appoints Mr. Anupam Jindal as Chief Financial Officer”.

Further note that the Board has authorized Mr. Anupam Jindal as a designated key managerial personnel for the purpose of determining materiality of events/information and make necessary disclosures to the stock exchanges as per the Company’s policy.

The above information will also be available on the website of the company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
### ANNEXURE A

**Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Particulars</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Name</td>
<td>Mr. Anupam Jindal</td>
</tr>
<tr>
<td>2.</td>
<td>Reason for change viz. appointment, resignation, removal, death or otherwise;</td>
<td>Appointment</td>
</tr>
<tr>
<td>3.</td>
<td>Date of appointment/ cessation (as applicable) &amp; term of appointment;</td>
<td>Effective from conclusion of the Board Meeting held on September 22, 2020.</td>
</tr>
<tr>
<td>4.</td>
<td>Brief profile (in case of appointment);</td>
<td>Refer Annexure B</td>
</tr>
<tr>
<td>5.</td>
<td>Disclosure of relationships between directors (in case of appointment of a director).</td>
<td>None</td>
</tr>
</tbody>
</table>

### ANNEXURE B

**BRIEF PROFILE OF MR. ANUPAM JINDAL**

Prior to joining Biocon, Mr. Anupam Jindal worked with the Vedanta Group of companies for 22 years where he held the position of Group Chief Financial Officer at Sterlite Technologies Limited since 2006. Anupam played a key role in growing the company’s revenue exponentially through organic capacity expansion and buyouts, in India and abroad. He was also instrumental in driving several strategic initiatives, such as inception and growth of new business verticals.

Anupam has a Bachelor of Commerce (B. Com) degree from ML Sukhadia University, Udaipur, Rajasthan. He is also a Chartered Accountant from the Institute of Chartered Accountants of India (‘ICAI’) and a Company Secretary from the Institute of Company Secretaries of India (‘ICSI’).
Press Release

Biocon appoints Anupam Jindal as its Chief Financial Officer

For immediate release

BENGALURU, India – September 22, 2020

Biocon Limited (BSE: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today that Anupam Jindal has been appointed as the company’s new Chief Financial Officer (CFO). Anupam will head the finance function at Biocon and be part of the Executive Leadership Team. He will report into the company’s Chief Executive Officer & Managing Director, Siddharth Mittal.

Prior to joining Biocon, Anupam worked with the Vedanta Group of companies for 22 years, where he held the position of Group Chief Financial Officer at Sterlite Technologies Limited since 2006. Anupam played a key role in growing the company’s revenue exponentially through organic capacity expansion and acquisitions, in India and abroad. He was also instrumental in driving several strategic initiatives, such as inception and growth of new business verticals.

Anupam holds a Bachelor of Commerce (B Com) degree from ML Sukhadia University, Udaipur. He is also a Chartered Accountant from the Institute of Chartered Accountants of India and a Company Secretary from the Institute of Company Secretaries of India.

Biocon’s Chief Executive Officer and Managing Director, Siddharth Mittal said, “We are pleased to have Anupam join us at this crucial phase of our growth, as we expand our portfolio and enter new geographies, to address patient needs for affordable, high-quality medicines. With his proven track record of steering high-growth companies, Anupam will play a key role in helping deliver on our business goals.”

About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Media:

BIOCON LIMITED
Calvin Printer
+91 80 2808 2132
Email: calvin.printer@biocon.com

Investor Relations:

BIOCON LIMITED
Saurabh Paliwal
+91 80 6775 2040
Email: investor.relations@biocon.com